Document is current
Any future updates will be listed below
-
Authors
Takashima, Shuichiro https://orcid.org/0000-0002-4200-5956
Sharma, Roshan https://orcid.org/0000-0001-9886-009X
Chang, Winston
Calafiore, Marco
Fu, Ya-Yuan https://orcid.org/0000-0002-3894-0490
Jansen, Suze A. https://orcid.org/0000-0002-1225-9963
Ito, Takahiro https://orcid.org/0000-0003-1008-647X
Egorova, Anastasiya
Kuttiyara, Jason
Arnhold, Viktor
Sharrock, Jessica
Santosa, Endi
Chaudhary, Ojasvi https://orcid.org/0000-0003-1434-2506
Geiger, Heather
Iwasaki, Hiromi
Liu, Chen
Sun, Joseph https://orcid.org/0000-0001-8062-9033
Robine, Nicolas https://orcid.org/0000-0001-5698-8183
Mazutis, Linas https://orcid.org/0000-0002-5552-6427
Lindemans, Caroline A.
Hanash, Alan M. https://orcid.org/0000-0002-3273-3634
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01-HL125571, R01-HL146338, R01-HL145631)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P30-CA008748)
- License Information
-
More Information
Article History
Received: 6 March 2024
Accepted: 27 November 2024
First Online: 2 January 2025
Competing interests
: The authors declare no competing financial interests. A.M.H. and C.A.L hold intellectual property related to Interleukin-22, and A.M.H. has a collaboration with Evive Biotechnology (Shanghai) Ltd, which supported a multicenter clinical trial studying use of Interleukin-22 in patients with GVHD. A.M.H. also serves in a volunteer capacity as a member of the Board of Directors of the American Society for Transplantation and Cellular Therapy (ASTCT).
